Produktname:2,5,6-Trichloronicotinamide
IUPAC Name:2,5,6-trichloropyridine-3-carboxamide
- CAS:142266-62-4
- Molekulare Formel:C6H3Cl3N2O
- Reinheit:95%+
- Katalognummer:CM177898
- Molekulargewicht:225.45
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:142266-62-4
- Molekulare Formel:C6H3Cl3N2O
- Schmelzpunkt:-
- SMILES-Code:O=C(N)C1=C(Cl)N=C(Cl)C(Cl)=C1
- Dichte:
- Katalognummer:CM177898
- Molekulargewicht:225.45
- Siedepunkt:
- Mdl-Nr.:
- Lagerung:Store at 2-8°C.
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Column Infos
- MK-1084
- Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.